We have a limited supply of COVID-19 vaccines and are offering them to eligible patients based on state and federal guidelines. Please do not call us for a vaccine appointment. We are notifying patients individually when they can schedule. so we can notify you. Learn more about the .
Clinical Trials and Research Studies
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)Learn More
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumorsLearn More
A PHASE 2 STUDY OF ALKS 4230 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED OR RECURRENT HEAD AND NECK SQUAMOUS CELL CANCER CURRENTLY ON TREATENT WITH ANTI-PD-(L)1 WITHOUT HAVING ACHIEVED A COMPLETE REMISSIONLearn More
A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid TumorsLearn More